US FDA issues warning letter to Lupin's Tarapur unit
The United States Food and Drug Administration (US FDA) has issued a warning letter to Lupin's Tarapur, Maharashtra facility, the company said in a stock exchange filing on Thursday. Lupin in a statement said it does not believe that the warning letter will have an impact or disruption of supplies or the existing revenues from operations of this facility. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 29, 2022 Category: Pharmaceuticals Source Type: news

At last, a drug to slow down Alzheimer's
Eisai Co, a Tokyo-based pharmaceutical company with a family bent and market capitalisation of $14 billion, crossed the finish line before behemoths valued nearly 20-fold higher, including industry leaders Roche Holding AG and Eli Lilly& Co (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 28, 2022 Category: Pharmaceuticals Source Type: news

Torrent Pharma to acquire Sequoia-backed Curatio Health for ₹2,000 cr
Curatio's portfolio consists of over 50 brands, including Tedibar, Atogla, Spoo, B4 Nappi, and Permite, which are ranked among the top five brands in their covered market. Dermatology accounts for 82% of Curatio's revenue. Within dermatology, cosmetic dermatology is a leading contributor. Its top 10 brands account for 75% of total revenue. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 27, 2022 Category: Pharmaceuticals Source Type: news

SII's Poonawalla makes clarion call for global certification of vaccines
"Multilateral organisations such as the United Nations and the World Trade Organisation should take it upon themselves to harmonise the certification of vaccines," he told PTI on the sideline of the conference, adding that "the world needs it if we want to be prepared in the future." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 27, 2022 Category: Pharmaceuticals Source Type: news

Torrent Pharma to acquire Sequoia-backed Curatio Health for $245 million
Torrent Pharma said that following the Curatio deal it will be among the top 10 companies in the dermatology segment in the country, according to an exchange filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 27, 2022 Category: Pharmaceuticals Source Type: news

Torrent Pharmaceuticals to acquire 100% of Curatio Healthcare for Rs 2,000 crores
Skincare product maker- Curatio has a strong presence in the cosmetic dermatology segment with a portfolio of over 50 brands, marketed in India. Curatio ’s portfolio consists of leading brands such as Tedibar, Atogla, Spoo, B4 Nappi, and Permite, which are ranked amongst top 5 brands in their covered market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 27, 2022 Category: Pharmaceuticals Source Type: news

'Anglo-French drugs to focus on specialty segments'
AFDIL president Nirbhay Kanoria told ET in an interview that the 100-year-old pharma company is focusing on specialty therapeutic segments such as orthopaedics, women's health, respiratory and insomnia, along with non-branded generics, with a focus on rural and semi-urban areas. He said the company has launched four divisions and is busy launching new products after the sale of brands to Lupin. "We are reorienting our sales approach from targeting general practitioners to more specialists-driven, in line with our new businesses," said Kanoria. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 26, 2022 Category: Pharmaceuticals Source Type: news

PAG-led API Platform acquire controlling stake in Optimus
Founded in 2004, Optimus is a vertically integrated manufacturer of pharmaceutical products, including advanced intermediates, active pharmaceutical ingredients (APIs), and finished drugs. It currently exports more than 100 products to 40 countries. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 26, 2022 Category: Pharmaceuticals Source Type: news

PLI schemes should also focus on entities supporting production of branded pharma products: Bharat Biotech
Production-linked incentive schemes should also focus on companies providing packaging materials and other services in addition to manufacturers of branded pharmaceutical items to reduce import dependence, according to Bharat Biotech Executive Director Sai Prasad. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 25, 2022 Category: Pharmaceuticals Source Type: news

Need to fast-track regulatory processes for biotech sector: Report
Globally, the biopharma drugs are expected to constitute over 40 per cent of the pharma market by 2030, presenting a significant opportunity for the Indian companies, it added. India is currently the third largest pharma industry in terms of volume and a source of 60,000 generic brands across 60 therapeutic categories. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 23, 2022 Category: Pharmaceuticals Source Type: news

Government forms committee to regulate marketing practices of pharma companies
The panel includes secretary of the department of pharmaceuticals S Aparna, Union health secretary Rajesh Bhushan, and Central Board of Direct Taxes (CBDT) chairman Nitin Gupta as members, and a joint secretary (policy) from the department of pharmaceuticals as member secretary. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 21, 2022 Category: Pharmaceuticals Source Type: news

SEC to review Bharat Bio's intranasal jab for use as booster soon
Covaxin - and has submitted the data to the Drugs Controller General of India (DCGI) for the review. Hyderabad based Bharat Biotech has sought market authorisation approval from Drugs Controller General of India (DCGI) for their intranasal heterologous booster in the 5-18 age group. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 21, 2022 Category: Pharmaceuticals Source Type: news

Plan to cap margins of key medicines in final stages
The Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers has sought tweaking of paragraph 19 of the DPCO for the fixation of the maximum retail price (MRP) of any class of non-scheduled drugs under TMR. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 17, 2022 Category: Pharmaceuticals Source Type: news

Glenmark bets on respiratory drug, licensing deals to improve business
Glenmark had gross debt of ₹3,765 crore as of June 30, 2022. The company over the years accumulated debt to fund its innovation-led R&D and fund capex, but with growth in key US market stuttering, it has been focusing on cutting debt and improving cash flows. In FY22, Glenmark reduced its debt by around ₹1,200 crore. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 15, 2022 Category: Pharmaceuticals Source Type: news

Ami Lifesciences appoints Amit Kaptain as CEO
As part of the Ami Lifesciences senior management team, Kaptain will be responsible for building business strategy and longstanding global partnerships with leading pharmaceutical companies by developing products in niche therapeutic areas, and thereby becoming a reliable partner of choice from India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 15, 2022 Category: Pharmaceuticals Source Type: news